Alterity AGM Seeks 25% Placement Capacity, Director Options and Auditor Swap to BDO
ATHE is trading near its 52-week low of $2.35 (0.9% above the low).
Summary
Alterity's AGM notice asks shareholders to approve a 25% placement capacity, 2.0M director options plus 3.7M options for CEO Stamler, his termination benefits, and the replacement of PwC with BDO as auditor. Nothing has been issued yet — these are authorizations up for a vote on 20 November 2026.
Key Events · Corporate Governance and Compliance · ATHE
-
25% Placement Capacity Sought
Resolution 4 seeks special approval of the extra 10% Listing Rule 7.1A mandate, taking total no-vote issuance capacity to 25% of issued capital for 12 months. Proceeds are earmarked for Phase 3 clinical trial costs and working capital.
-
Director and CEO Option Grants
2,000,000 options (500,000 each) to Marks, Gozlan, Babarczy and Cunningham at A$1.00, valued at A$165,985 each; 3,700,008 options to CEO Stamler at A$1.00 vesting in three equal annual tranches, valued at US$524,497.
-
CEO Termination Benefits Up for Vote
Approval sought for up to 6 months' salary in lieu of notice (US$262,500), 100% base salary (US$525,000) on good-reason or without-cause termination, 1x base plus target bonus on a change-of-control resignation, and full vesting of up to 3,700,008 options.
-
Auditor Change: PwC Out, BDO In
PricewaterhouseCoopers has notified its intention to resign effective at the meeting; BDO Audit Pty Ltd, nominated by the Company Secretary, is proposed as auditor from the close of the meeting.
Analysis · ATHE · Life Sciences
Shareholders are being asked to lift placement capacity from 15% to 25% of issued capital under ASX Listing Rule 7.1A — headroom the company says would fund Phase 3 ATH434 trial costs and working capital. That matters because Alterity's FY2026 20-F carried going concern language with roughly 5.2 quarters of runway, so expanded issuance capacity is a dilution lever the board wants pre-approved. The same meeting seeks 2,000,000 options for the four non-executive directors and 3,700,008 options for CEO David Stamler (together valued at about A$663,941 and US$524,497 respectively), plus approval of Stamler's termination benefits of up to 1x base salary (US$525,000) and full equity acceleration on a change of control. Separately, PwC is resigning and BDO Audit is nominated as replacement — a change worth noting given the going concern disclosure. All items are approvals only; no shares or options have been issued yet.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.2% of the 1544 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $2.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $2.35 to $5.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.